Player FM - Internet Radio Done Right
40 subscribers
Checked 4M ago
تمت الإضافة منذ قبل eight عام
المحتوى المقدم من MediCom Oncology. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة MediCom Oncology أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
المدونة الصوتية تستحق الاستماع
برعاية
Y
You Can’t Make This Up


At the dawn of the social media era, Belle Gibson became a pioneering wellness influencer - telling the world how she beat cancer with an alternative diet. Her bestselling cookbook and online app provided her success, respect, and a connection to the cancer-battling influencer she admired the most. But a curious journalist with a sick wife began asking questions that even those closest to Belle began to wonder. Was the online star faking her cancer and fooling the world? Kaitlyn Dever stars in the Netflix hit series Apple Cider Vinegar . Inspired by true events, the dramatized story follows Belle’s journey from self-styled wellness thought leader to disgraced con artist. It also explores themes of hope and acceptance - and how far we’ll go to maintain it. In this episode of You Can't Make This Up, host Rebecca Lavoie interviews executive producer Samantha Strauss. SPOILER ALERT! If you haven't watched Apple Cider Vinegar yet, make sure to add it to your watch-list before listening on. Listen to more from Netflix Podcasts .…
What is the current status of immunotherapy in pancreatic cancer?
Manage episode 184110663 series 1375096
المحتوى المقدم من MediCom Oncology. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة MediCom Oncology أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Listen as Dr. O'Reilly discusses the the current status of immunotherapy in pancreatic cancer.
…
continue reading
53 حلقات
Manage episode 184110663 series 1375096
المحتوى المقدم من MediCom Oncology. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة MediCom Oncology أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Listen as Dr. O'Reilly discusses the the current status of immunotherapy in pancreatic cancer.
…
continue reading
53 حلقات
كل الحلقات
×
1 Third-generation FLT3 inhibitors in clinical development 2:42
2:42
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب2:42
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.

1 CAR T case study in acute myeloid leukemia 5:49
5:49
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب5:49
Dr. Sallman describes a patient case demonstrating promise in the further study and potential use of CAR T-cell therapy for patients with AML.

1 Key considerations when prescribing midostaurin with a strong CYP3A4 inhibi 2:23
2:23
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب2:23
Dr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.

1 How to proceed with a patient who presents with idiopathic cytopenia of undetermined significance 3:58
3:58
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب3:58
In this audio activity, Dr. Goldberg describes his approach to patients with idiopathic or clonal cytopenias of undetermined significance (ICUS and CCUS).

1 When to consider iron chelation therapy for a transplant-eligible patient 3:56
3:56
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب3:56
Listen as Dr. Goldberg explains his approach to iron chelation therapy in patients who are, or may be within the next 5-10 years, eligible for transplant.

1 53-year-old woman presenting with severe fatigue and bruising 3:58
3:58
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب3:58
Hematopathologist Dr. Khoury presents a case snapshot showing the complexities of diagnosing AML, describing the importance of morphology, flow cytometry, cytogenetics, and molecular diagnostics.

1 New subcategories of pancreatic cancer allow for a biomarker-driven approach to therapy 4:00
4:00
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب4:00
Dr. O'Reilly discusses the new subcategories of pancreatic cancer that have emerged, and which are laying the groundwork for a biomarker-driven approach to therapy.

1 What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics? 2:40
2:40
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب2:40
Dr. O'Reilly discusses the unique pathophysiology of pancreas cancer that must be considered in the development of novel therapeutics.

1 Predictors of response to lenalidomide in a non-del(5q) MDS patient 3:03
3:03
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب3:03
Listen as Dr. Goldberg discusses, in just under two minutes, the predictors of response to lenalidomide in a non-del(5q) MDS patient.

1 What are the pros and cons of radiation therapy? 2:29
2:29
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب2:29
Listen as Dr. Matasar discusses the pros and cons of radiation therapy, and who should be offered this therapy.

1 What defines high-quality survivorship care for patients treated for classical Hodgkin lymphoma? 3:01
3:01
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب3:01
Listen as Dr. Matasar discusses survivorship care for patients who have been treated for classical Hodgkin lymphoma, including late effects of treatment.

1 Second primary malignancies associated with lenalidomide maintenance 2:53
2:53
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب2:53
Dr. Jacob Laubach discusses second primary malignancies associated with lenalidomide maintenance in the transplant and post-transplant setting.

1 Impact of consolidation therapy in patients post-transplant 3:09
3:09
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب3:09
Dr. Laubach discusses the impact of consolidation therapy in patients post-transplant, referencing results of the CTN StaMINA trial.

1 Bortezomib as an alternate strategy for maintenance therapy. 2:32
2:32
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب2:32
Dr. Jacob Laubach discusses bortezomib as an alternate strategy to lenalidomide for maintenance therapy in patients with multiple myeloma.

1 What may be the future role for brentuximab vedotin in newly diagnosed Hodgkin lymphoma? 2:35
2:35
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب2:35
Listen as Dr. Matasar discusses the future role of brentuximab vedotin in patients with newly diagnosed classical Hodgkin lymphoma.
مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.